SecBot SecBot
3 ·Filed Jun 1, 2026

OKYO

OKYO Pharma Ltd
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001493152-26-026685
Form 3 — initial insider ownership statement
Actionable Insight • Neutral

This Form 3 is a standard initial ownership filing for a new insider and carries no trading signal. Monitor for any future Form 4 filings that would indicate open-market buying or selling by Brancaccio, which could provide a more actionable signal on insider sentiment.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
OKYO ▼ -8.82% at T+60d
NEUTRAL call -8.82% · α vs SPY -9.94% · entry $1.70 → $1.55
Entry = T+0 close
Jun 1, 2026
via day close
T+1d
-2.35%
call -2.35% · α -1.63%
$1.66
settled 5mo ago
T+5d
-9.41%
call -9.41% · α -6.45%
$1.54
settled 5mo ago
T+20d
-11.76%
call -11.76% · α -10.20%
$1.50
settled 4mo ago
T+60d
-8.82%
call -8.82% · α -9.94%
$1.55
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

John P. Brancaccio filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing his holdings in OKYO Pharma Ltd as of March 18, 2026. He reported 30,201 shares of common stock and a large number of vested and unvested stock options with exercise prices ranging from $1.46 to $2.13, expiring between 2033 and 2035. This is a routine initial ownership disclosure for a new insider and contains no trading activity or material corporate event.

Key Facts

  • John P. Brancaccio filed Form 3 as an initial statement of beneficial ownership.
  • Brancaccio directly owns 30,201 shares of OKYO Pharma common stock.
  • He holds multiple tranches of stock options exercisable for common stock, with exercise prices between $1.46 and $2.13, expiring from 2033 to 2035.
  • The filing is dated as of March 18, 2026, and was submitted on June 1, 2026.
  • No open-market purchases or sales are reported; this is a disclosure of existing holdings.

Financial Impact

No financial impact; the filing is a routine insider ownership disclosure with no transaction or corporate action.

Risk Factors

  • No material risks identified from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001493152-26-026685
Document: 0001493152-26-026685-index.html0001493152-26-026685
Document: 0001493152-26-026685.txt0001493152-26-026685
29 reports for OKYO
Performance horizon
50% Hit rate @ T+1 5 of 10 directional calls Went positive at some point 7 of 10 best @ T+5▲ +13.89%Jul 21, 2026
Filters
Rows
Reports for OKYO — sortable, filterable
TypeNow
Oct 6, 2026
21d ago
6-K
BULLISH ★ 6/10
$1.46 $1.41▼ −3.42%▼ −3.18%$1.49 (+2.05%)
Oct 6, 2026
21d ago
Press Release
BULLISH ★ 6/10
$1.46 $1.41▼ −3.42%▼ −3.18%$1.49 (+2.05%)
Sep 29, 2026
28d ago
6-K
NEUTRAL ★ 3/10
$1.36 $1.29▼ −5.15%▼ −4.94%$1.49 (+9.56%)
Sep 8, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$1.53 $1.45▼ −5.23%▼ −4.76%$1.49 (−2.61%)
Aug 7, 2026
11w ago
Insider Cluster
BULLISH ★ 5/10
$1.57 $1.52▼ −3.18%▼ −2.87%$1.49 (−5.10%)
Jul 28, 2026
13w ago
6-K
NEUTRAL ★ 3/10
$1.64 $1.64· 0.00%▲ +1.54%$1.49 (−9.15%)
Jul 27, 2026
13w ago
6-K
NEUTRAL ★ 2/10
$1.64 $1.64· 0.00%▼ −0.24%$1.49 (−9.15%)
Jul 23, 2026
13w ago
6-K
NEUTRAL ★ 2/10
$1.48 $1.55▲ +4.73%▲ +4.63%$1.49 (+0.68%)
Jul 23, 2026
13w ago
Press Release
NEUTRAL ★ 2/10
$1.48 $1.55▲ +4.73%▲ +4.63%$1.49 (+0.68%)
Jul 23, 2026
13w ago
6-K
BULLISH ★ 4/10
$1.48 $1.55▲ +4.73%▲ +4.63%$1.49 (+0.68%)
Showing 10 of 29

US Market Status

Market Closed — Opens Thu (9h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026